Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

NCT05574504 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI Decision based on no enrollment

Conditions

Metastatic Cancer
Urothelial Carcinoma

Interventions

DRUG: avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin

Sponsor

AdventHealth

Collaborators

[object Object]